Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen
Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen Uses, Dosage, Side Effects, Food Interaction and all others data.
Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
Trade Name | Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen |
Generic | Axalimogene filolisbac |
Axalimogene filolisbac Other Names | Adxs hpv, Live, attenuated listeria monocytogenes bacteria, expressing human papilloma virus type 16-e7 tumor antigen, Raligize |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
![Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen](https://www.medicinesfaq.com/media/png/expressing-human-papilloma-virus-type-16-e7-tumor-antigen.png)
Innovators Monograph
You find simplified version here Expressing Human Papilloma Virus Type 16-e7 Tumor Antigen